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Systemic infusion of bone marrow mesenchymal
stem cells (BMMSCs) yields therapeutic benefit for
a variety of autoimmune diseases, but the underlying
mechanisms are poorly understood. Here we show
that in mice systemic infusion of BMMSCs induced
transient T cell apoptosis via the FAS ligand (FASL)-
dependent FAS pathway and could ameliorate
disease phenotypes in fibrillin-1 mutated systemic
sclerosis (SS) and dextran-sulfate-sodium-induced
experimental colitis. FASL/ BMMSCs did not
induce T cell apoptosis in recipients, and could not
ameliorate SS and colitis. Mechanistic analysis re-
vealed that FAS-regulated monocyte chemotactic
protein 1 (MCP-1) secretion by BMMSCs recruited
T cells for FASL-mediated apoptosis. The apoptotic
T cells subsequently triggered macrophages to
produce high levels of TGFb, which in turn led to
the upregulation of CD4+CD25+Foxp3+ regulatory
T cells and, ultimately, immune tolerance. These
data therefore demonstrate a previously unrecog-
nized mechanism underlying BMMSC-based immu-
notherapy involving coupling via FAS/FASL to induce
T cell apoptosis.
INTRODUCTION
Mesenchymal stem cells (MSCs) display profound immunomod-
ulatory properties by inhibiting proliferation and function of
several major immune cells, such as dendritic cells, T and B
lymphocytes, and natural killer (NK) cells (Nauta and Fibbe,
2007; Uccelli et al., 2007, 2008; Aggarwal and Pittenger, 2005).
These unique properties have prompted researchers to investi-
gate mechanisms by which MSCs ameliorate a variety of
immune disorders (Nauta and Fibbe, 2007; Bernardo et al.,
2009). In fact, MSC-based therapy has been successfully
applied in various human diseases, including graft versus host544 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.disease (GvHD), systemic lupus erythematosus (SLE), rheuma-
toid arthritis, autoimmune encephalomyelitis, inflammatory
bowel disease, and multiple sclerosis (Aggarwal and Pittenger,
2005; Le Blanc et al., 2004; Chen et al., 2006; Polchert et al.,
2008; Sun et al., 2009; Augello et al., 2007; Parekkadan et al.,
2008; Zappia et al., 2005; Gonza´lez et al., 2009; Liang
et al., 2009). The immunosuppressive properties of MSCs are
associated with the production of cytokines, such as interleukin
10 (IL10), nitric oxide (NO), indoleamine 2,3-dioxygenase (IDO),
prostaglandin (PG) E2, and TSG-6 (Batten et al., 2006; Zhang
et al., 2010; Ren et al., 2008; Sato et al., 2007; Meisel et al.,
2004; Aggarwal and Pittenger, 2005; Choi et al., 2011; Roddy
et al., 2011). In addition, MSC-induced immune tolerance
involves upregulation of CD4+CD25+Foxp3+ regulatory T cells
(Tregs) and downregulation of proinflammatory T helper 17
(Th17) cells (Sun et al., 2009; Gonza´lez et al., 2009; Park et al.,
2011). However, the detailed mechanism of MSC-based immu-
notherapy is not fully understood. In this study, we show that
MSC-induced T cell apoptosis through FAS signaling is required
for MSC-mediated therapeutic effects in systemic sclerosis (SS)
and experimental colitis in mice.
RESULTS
FAS Ligand in Bone Marrow MSCs Induces T Cell
Apoptosis
Since bonemarrowMSCs (BMMSCs) express FAS ligand (FASL)
and activated T cells express elevated levels of FAS (Mazar et al.,
2009; Figures S1A–S1D available online), we hypothesized that
FASL-mediated FAS signaling might play a critical role in
BMMSC-based immunomodulation. To test this hypothesis,
BMMSCs from C57BL6 mice, fasl-mutated B6Smn.C3-
FASLgld/J mice (gldBMMSC), and fasl-transfected gldBMMSCs
(FASL+gldBMMSCs) were injected into normal C57BL6 mice
(Figure 1A). Peripheral blood and bone marrow samples were
collected at 0, 1.5, 6, 24, and 72 hr after BMMSC transplantation
(BMMSCT) (Figure 1A). Allogenic BMMSC infusion reduced the
number of CD3+ T cells and increased the number of apoptotic
CD3+Tcells in peripheral blood, bonemarrow, spleen, and lymph
node starting at 1.5 hr, reaching the peak at 6 hr, and lasting until
72 hr posttransplantation (Figures 1B–1E; S1P–S1S). In order to
Figure 1. BMMSCs Induce T Cell Apoptosis via FAS Ligand
(A) Schema of BMMSCT procedure. 13106 BMMSCs (n = 5), FASL/ gldBMMSCs (n = 4), or fasl-transfected gldBMMSCs (FASL+gldBMMSCs, n = 4) were
infused into C57BL6 mice through the tail vein. All groups were sacrificed at indicated time points for sample collection. Zero hour represents mice immediately
sacrificed after BMMSC injection.
(B–E) BMMSCT induced transient reduction in the number of CD3+ T cells and increased AnnexinV+7AAD+ double positive apoptotic CD3+ T cells in peripheral
bloodmononuclear cells (PBMNCs; B andC) and bonemarrowmononuclear cells (BMMNCs; D and E) at indicated time points, while FASL/BMMSCs from gld
mice (gldBMMSCs) failed to reduce CD3+ T cells or elevate CD3+ T cell apoptosis in peripheral blood (B and C) and bone marrow (D and E). Fasl-transfected
gldBMMSC transplantation (FASL+gldBMMSC) partially rescued the capacity to reduce the number of CD3+ T cells and induce CD3+ T cell apoptosis
in peripheral blood (B and C) and bone marrow (D and E). *p < 0.05; **p < 0.01; ***p < 0.005 versus gldBMMSC; #p < 0.05; ###p < 0.005 versus FASL+gldBMMSC;
$p < 0.05; $$$p < 0.005 versus gldBMMSC.
(F) When BMMSCs were infused into mice, TUNEL and immunohistochemistry staining showed that the TUNEL-positive apoptotic cell (brown, white arrow)
number in CD3+ T cells (purple, yellow arrowhead) was higher in the BMMSC-injected group compared to the control group in bone marrow. Bar = 50 mm.
(G) When BMMSCs were cocultured with T cells, BMMSC-induced AnnexinV+7AAD+ double positive apoptotic T cells were significantly blocked by anti-FASL
neutralizing antibody (1 mg/mL) compared to IgG antibody control group.
(H) TUNEL and immunohistochemistry staining showed that TUNEL-positive apoptotic T cells (brown, white arrow) were observed in CD3+ T cells (purple, yellow
arrowhead) when cocultured with BMMSCs in vitro. In the presence of anti-FASL neutralizing antibody (FASL Ab), TUNEL-positive cell percentage was signif-
icantly less than that of the untreated control group. Bar = 50 mm.
(I) In addition, the number of BMMSC-induced AnnexinV+7AAD+ double positive apoptotic T cells was significantly blocked by caspase 3, 8, and 9 inhibitor
treatments. The results were representative of three independent experiments.
(J) Schematic diagram indicating that BMMSCs induce T cell apoptosis.
*p < 0.05; **p < 0.01; ***p < 0.005. Error bars: mean ± SD. See also Figures S1 and S2.
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FAS/FAS Ligand and Cell-Based Immunotherapycompare syngenic and allogenic BMMSCs, we showed that
BMMSCs derived from a littermate were the same as allogenic
BMMSCs in their capacity to induce T cell apoptosis (Figures
S2A–S2G). Meanwhile, infusion of FASL/ gldBMMSCs failedto reduce the number of CD3+ T cells or elevate the number of
apoptotic CD3+ T cells in peripheral blood and bone marrow
(Figures 1B–1E). However, overexpression of fasl in gldBMMSCs
by lentiviral transfection (Figure S1N) partially rescued theCell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc. 545
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FAS/FAS Ligand and Cell-Based Immunotherapycapacity to reduce the number of CD3+ T cells and elevate the
number of apoptotic CD3+ T cells in peripheral blood and
bone marrow (Figures 1B–1E). BMMSC infusion also resulted
in the reduction of the number of both CD4+ and CD8+ T cells,
with a correspondingly increased number of apoptotic CD4+
and CD8+ T cells in peripheral blood (Figures S1E and S1F).
Interestingly, BMMSCT induced CD4+ T cell apoptosis and
Treg upregulation in OT1 TCR TG mice. However, the
percentage of CD8+ T cells, which react with OVA-MHC class
I antigen, was unchanged after BMMSCT, indicating that trans-
planted BMMSCs need to be recognized as antigens to initiate
CD8+ T cell apoptosis (Figures S1T–S1AA). TUNEL staining
confirmed that BMMSC infusion elevated the number of
apoptotic T cells in bone marrow (Figure 1F). We next verified
that BMMSC-induced T cell death was caused by apoptosis
based on the in vitro blockage of BMMSC-induced CD3+
T cell apoptosis by neutralizing FASL antibody and caspase 3,
8, and 9 inhibitors (Figures 1G–1I). FASL neutralizing antibody
injection could partially block BMMSC-induced CD3+ T cell
apoptosis, upregulation of Tregs, and downregulation of Th17
cells in peripheral blood and bone marrow (Figures S1G–S1M).
These data indicate that BMMSCs are capable of inducing
T cell apoptosis through the FASL/FAS signaling pathway (Fig-
ure 1J). Although BMMSCs failed to induce naive T cell
apoptosis in the coculture system (data not shown), they were
able to induce activated T cell apoptosis in vitro (Figures 1G
and 1I).
In order to confirm the role of FASL in BMMSC-mediated
T cell apoptosis in vivo, we used siRNA to knock down fasl
expression in BMMSCs (Figure S3A) and infused these into
C57BL6 mice. As expected, this failed to reduce the number
of CD3+ T cells or induce CD3+ T cell apoptosis in peripheral
blood and bone marrow (Figures 2A–2D). Moreover, infusion of
these fasl knockdown BMMSCs failed to elevate Treg levels in
peripheral blood (Figure 2E). This study confirms that FASL is
required for BMMSC-induced T cell apoptosis and Treg
upregulation.
Since apoptotic T cells trigger TGFb production by macro-
phages and upregulate Tregs, which leads to immune tolerance
in vivo (Perruche et al., 2008), we examined whether BMMSC-
induced T cell apoptosis could also promote the upregulation
of Tregs. We found that systemic infusion of BMMSCs did, in
fact, elevate Treg levels in peripheral blood at 24 and 72 hr post-
transplantation (Figure 2F; S2H–S2M), as well as elevate TGFb
levels and reduce Th17 cell levels in peripheral blood (Figure 2G;
S1O). Cotransplantation of BMMSCs and pan T cells resulted in
T cell apoptosis at 1.5 and 6 hr posttransplantation. On the other
hand, FASL/ gldBMMSC infusion failed to upregulate the
levels of either Tregs or TGFb (Figures 2F and 2G), suggesting
that FASL-mediated T cell apoptosis plays a critical role in
Treg upregulation. Indeed, overexpression of fasl in FASL/
gldBMMSCs rescued BMMSC-induced Treg upregulation and
TGFb production at 24 hr posttransplantation (Figures 2F
and 2G).
To examine the mechanism by which BMMSC infusion re-
sulted in TGFb upregulation in peripheral blood, we used fluores-
cence analysis to confirm that macrophages engulfed apoptotic
T cells in vivo (Perruche et al., 2008; Figure 2H). Then we
measured the number of CD11b+ macrophages in spleen cells546 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.and found that the number was significantly increased in the
BMMSC infusion group (Figure 2I). In contrast, treatment with
macrophage inhibitor clodronate liposomes significantly
reduced the number of CD11b+ macrophages in spleen cells
(Figure 2I) and blocked BMMSC infusion-induced upregulation
of TGFb and Tregs (Figures 2J and 2K). These data suggest
that T cell apoptosis, as induced by BMMSC infusion, activates
macrophages to produce the TGFb that results in Treg upregula-
tion (Figure 2L).
We next asked whether apoptosis of infused BMMSCs also
triggers macrophages to produce TGFb to upregulate Tregs.
Carboxyfluorescein diacetate N-succinimidyl ester (CFSE)-
labeled BMMSCs, gldBMMSCs, and fasl knockdown BMMSCs
were infused into C57BL6 mice. At 1.5 hr postinfusion, all
CFSE+ cells were detected and reached a peak in peripheral
blood and bone marrow, after which the cell number was grad-
ually decreased, becoming undetectable at 24 hr postinfusion
(Figures S3C and S3D). In contrast, CFSE+ apoptotic cells
reached a peak at 6 hr postinfusion and became undetectable
at 24 hr postinfusion in peripheral blood and bone marrow
(Figures S3E and S3F). The apoptosis of transplanted BMMSCs
was also observed by immunofluorescent analysis (Figure S3B).
Although apoptosis of the infused FASL-deficient BMMSCs was
observed, no corresponding upregulation of TGFb or Tregs was
observed in peripheral blood (Figures 2E–2G). These data
suggest that T cell, not BMMSC, apoptosis is required for Treg
upregulation (Figure 2L).
FASL Is Required for BMMSC-Based Immune Therapies
in Both Tight-Skin SS and Inductive Experimental Colitis
Mice
To further study the therapeutic mechanism of BMMSCT, two
mouse models, genetic tight-skin (Tsk/+) SS and inductive
experimental colitis, were used to evaluate the therapeutic effect
of BMMSCT. Allogenic normal BMMSCs or gldBMMSCs
(13106) were systemically transplanted into Tsk/+ SS mice
(Green et al., 1976) at 8 weeks of age, and samples were har-
vested at 12 weeks of age for further evaluation (Figure 3A).
The BMMSC-transplanted group showed significant reduction
in the number of CD3+ T cells and corresponding elevation in
the number of apoptotic CD3+ T cells in peripheral blood from
6 to 72 hr posttransplantation (Figures 3B and 3C). On the other
hand, FASL/ gldBMMSC transplantation failed to induce CD3+
T cell apoptosis (Figures 3B and 3C).
Tsk/+mice showed an increase in the levels of antinuclear anti-
body (ANA), anti-double strand DNA (dsDNA) IgG and IgM anti-
bodies, creatinine in serum, and urine proteins (Figures 3D–3H).
Normal BMMSC, but not FASL/ gldBMMSC, transplantation
significantly reduced the levels of ANA, dsDNA IgG and IgM,
serumcreatinine, and urine protein levels (Figures 3D–3H). More-
over, BMMSCT rescued decreased levels of Tregs and
increased levels of Th17 cells in Tsk/+ mice (Figures 3I and 3J;
S4B). As expected, gldBMMSC transplantation failed to regulate
the levels of Tregs and Th17 cells in Tsk/+ mice (Figures 3I and
3J). Histological analysis also showed that skin hypodermal
(HD) thickness was significantly increased in Tsk/+ mice (Fig-
ure 3K). After BMMSCT, HD thickness was reduced to a level
equal to that of the control group, whereas gldBMMSC failed
to reduce HD thickness (Figure 3K). Additionally, the tightness
Figure 2. FASL Is Required for BMMSC-Induced T Cell Apoptosis and Upregulation of CD4+CD25+Foxp3+ Regulatory T Cells
(A and B) BMMSCT (BMMSC, n = 5) induced a transient reduction in the number of CD3+ T cells (A) and elevation of AnnexinV+7AAD+ double positive apoptotic
CD3+ cells (B) in peripheral blood. Transplantation of fasl knockdown BMMSCs (FASL siRNA BMMSC, n = 3) failed to reduce the number of CD3+ T cells (A) or
increase the number of CD3+ apoptotic T cells (B) in peripheral blood.
(C and D) BMMSCT (BMMSC, n = 5) resulted in a transient reduction of CD3+ T cells (C) and elevation of AnnexinV+7AAD+ double positive apoptotic CD3+ T cells
(D) in bone marrow. Transplantation of fasl knockdown BMMSCs (FASL siRNA BMMSC, n = 3) failed to reduce the number of CD3+ T cells (C) or elevate the
number of CD3+ apoptotic T cells (D) in bone marrow.
(E) BMMSC, but not fasl knockdown BMMSC, transplantation significantly upregulated levels of CD4+CD25+Foxp3+ regulatory T cells (Tregs) at 24 and 72 hr after
transplantation in C57BL6 mice.
(F) BMMSCT resulted in a significant upregulation of Tregs when compared to the gldBMMSC transplantation group at 24 and 72 hr posttransplantation. fasl-
transfected gldBMMSC transplantation (FASL+gldBMMSC) partially rescued BMMSC-induced upregulation of Tregs.
(G) TGFb level in peripheral blood was significantly increased in both BMMSC and FASL+gldBMMSC groups at 24 hr posttransplantation. FASL/ gldBMMSC
transplantation failed to upregulate TGFb level.
(H) Apoptotic pan T cells were engulfed by macrophages in vivo. Green indicates T cells, and red indicates CD11b+ macrophages. Bar = 50 mm.
(I) BMMSCT group increased the number of CD11b+ cells in peripheral blood when compared to the control group (C57BL6). Depletion of macrophages by
clodronate liposome treatment showed the effectiveness in reducing CD11b+ cells in the BMMSCT group (BMMSC+clodronate), as assessed by flow cytometric
analysis.
(J) TGFb level was significantly increased in peripheral blood after BMMSCT. Clodronate liposome treatment blocked BMMSC-induced upregulation of TGFb
(BMMSC+clodronate).
(K) BMMSCT upregulated the level of Tregs in peripheral blood compared to the control group (C57BL6). Clodronate liposome treatment inhibited BMMSC-
induced Treg upregulation (BMMSC+clodronate).
(L) Schematic diagram indicating that BMMSC-induced T cell apoptosis resulted in immune tolerance as evidenced by upregulation of Tregs. The results were
representative of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Figure S3.
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FAS/FAS Ligand and Cell-Based Immunotherapyof skin, as measured by Grabbed distance, was significantly
improved in the BMMSC, but not the gldBMMSC, transplanta-
tion group (Figure S4A).The induced experimental colitis model was generated as
previously described (Alex et al., 2009; Zhang et al., 2010). Allo-
genic normal BMMSCs or FASL/ gldBMMSCs (13106) wereCell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc. 547
Figure 3. FASL Is Required for BMMSC-Mediated Amelioration of Systemic Sclerosis Phenotypes
(A) Schema showing howBMMSCT ameliorates systemic sclerosis (SS) phenotype. (B andC) BMMSCT (n = 6) resulted in a significantly reduced number of CD3+
T cells (B) and increased number of AnnexinV+7AAD+ double positive apoptotic CD3+ T cells (C) in SS mice as assessed by flow cytometric analysis. However,
FASL/ gldBMMSCs (n = 6) failed to reduce the number of CD3+ T cells (B) or elevate the number of apoptotic CD3+ T cells (C).
(D–F) Tsk/+ SS mice showed elevated levels of antinuclear antibody (ANA) (D) and anti-double strand DNA antibodies IgG (E) and IgM (F) when compared to
control C57BL6 mice. BMMSCT reduced the levels of ANA (D) and anti-double strand DNA antibodies IgG (E) and IgM (F). In contrast, FASL/ gldBMMSC
transplantation failed to reduce the levels of ANA (D) or anti-double strand DNA IgG (E) and IgM (F) antibodies.
(G) Creatinine level in serum was significantly increased in Tsk/+ mice. After BMMSCT, creatinine level was significantly decreased to the level observed in
C57BL6 mice. However, gldBMMSC transplantation failed to reduce the creatinine level.
(H) The concentration of urine protein was significantly increased in Tsk/+ mice. BMMSCT reduced urine protein to the control level. gldBMMSC transplantation
failed to reduce urine protein levels in Tsk/+ mice.
(I) Treg level was significantly decreased in Tsk/+ mice compared to C57BL6 mice. After BMMSCT, Treg levels were significantly elevated, whereas gldBMMSC
transplantation failed to increase Treg levels in Tsk/+ mice.
(J) CD4+IL17+ Th17 cells were significantly increased in Tsk/+ mice compared to C57BL6 mice. Elevated Th17 level was significantly reduced in the BMMSCT
group, while gldBMMSC transplantation failed to reduce the Th17 level in Tsk/+ mice.
(K) Hyperdermal thickness was significantly increased in Tsk/+ mice (Tsk/+, n = 5) compared to control mice (C57BL6, n = 5). BMMSC, but not FASL/
gldBMMSC, transplantation reduced hyperdermal thickness.
*p < 0.05, **p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Figure S4.
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after 3% dextran sulfate sodium (DSS) induction (Zhang et al.,
2010; Figure 4A). Normal BMMSCT reduced the number of
CD3+ T cells and elevated the number of AnnexinV+7AAD+
double positive apoptotic CD3+ T cells in peripheral blood start-
ing at 1.5 hr and lasting to 72 hr after transplantation (Figures 4B
and 4C). However, the gldBMMSC transplantation group
showed no difference from the colitis group in terms of numbers
of CD3+ T cells and apoptotic CD3+ T cells (Figures 4B and 4C).
The body weight of mice with induced colitis was significantly548 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.reduced compared to that of control C57BL6 mice from day 5
to 10 post-DSS induction (Figure 4D). After normal BMMSC,
but not gldBMMSC, transplantation, the body weight was
partially restored at day 10 post-DSS induction. The disease
activity index (DAI), including body weight loss, diarrhea, and
bleeding, was significantly elevated in the colitis mice compared
to the control mice. After BMMSCT, the DAI score was
decreased, while gldBMMSCs failed to reduce the DAI score
(Figure 4E). Both decreased Tregs and elevated Th17 cells
were observed in the colitis mice from day 7 to 10 post-DSS
Figure 4. FASL Plays a Critical Role in BMMSC-Mediated Immune Therapy for Dextran-Sulfate-Sodium-Induced Experimental Colitis
(A) Schema showing BMMSCT in dextran sulfate sodium (DSS)-induced experimental colitis mice.
(B and C) BMMSCT (n = 6) resulted in a significantly reduced number of CD3+ T cells at 24 hr posttransplantation (B) and increased number of AnnexinV+7AAD+
double positive apoptotic CD3+ T cells at 24–72 hr posttransplantation (C) in colitismice as assessed by flow cytometric analysis. However, FASL/ gldBMMSCs
(n = 6) failed to reduce the number of CD3+ T cells (B) or elevate the number of apoptotic CD3+ T cells (C). **p < 0.01 versus Colitis, ***p < 0.005 versus Colitis, #p <
0.05 versus gldBMMSC, ##p < 0.01 versus gldBMMSC, ###p < 0.005 versus gldBMMSC.
(D) Colitis mice (colitis, n = 5), BMMSCT group, and gldBMMSC mice showed significantly reduced body weight from 5 to 10 days after DSS induction. The
BMMSCT group showed inhibition of body weight loss compared to the colitis and gldBMMSC transplantation groups at 10 days after DSS induction. *p < 0.05
versus C57BL6, ***p < 0.005 versus C57BL6, ###p < 0.005 versus BMMSC.
(E) Disease activity index (DAI) was significantly increased in colitis mice compared to C57BL6 mice from 5 days to 10 days after DSS induction. BMMSCT
significantly reduced the DAI score, but it was still higher than that observed in C57BL6mice. FASL/ gldBMMSC transplantation failed to reduce DAI score at all
time points.
(F) Treg level was significantly reduced in colitis mice compared to C57BL6 mice at 7 days after DSS induction. BMMSC, but not FASL/gldBMMSC, trans-
plantation upregulated the Treg levels in colitis mice. *p < 0.05 versus C57BL6, ***p < 0.005 versus C57BL6, #p < 0.05 versus BMMSC, ###p < 0.005 versus
BMMSC.
(G) Th17 cell level was significantly elevated in colitis mice compared to C57BL6 mice at 7 days after DSS induction. BMMSC, but not FASL/gldBMMSC,
transplantation reduced the levels of Th17 cells in colitis mice from 7 to 10 days after DSS induction. ***p < 0.005 versus C57BL6, ###p < 0.005 versus BMMSC.
(H) Hematoxylin and eosin staining showed the infiltration of inflammatory cells (blue arrows) in colon with destruction of epithelial layer (yellow triangles) in colitis
mice. BMMSC, but not FASL/gldBMMSC, transplantation rescued disease phenotype in colon and reduced histological activity index.
(I) Schematic diagram of BMMSCT for immunotherapies.
Scale bar = 200 mm; *p < 0.05, **p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Figure S5.
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transplantation significantly upregulated Tregs and downregu-
lated Th17 cells (Figures 4F and 4G). Furthermore, colon tissue
from each group was analyzed (Figure 4H). Both the absence
of epithelial layer and infiltration of inflammatory cells were
observed in the colitis and gldBMMSC transplantation groups.BMMSCT recovered epithelial structure and eliminated inflam-
matory cells in colitis mice. Histological activity index (Alex
et al., 2009) confirmed that BMMSCT reduced the DAI, while
gldBMMSCs failed to improve the DAI (Figure 4H). The data
therefore suggest that BMMSC-induced T cell apoptosis with
Treg upregulation might offer a potential treatment for the colitisCell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc. 549
Figure 5. FAS Plays an Essential Role in BMMSC-Mediated CD3+ T Cell Apoptosis and Upregulation of Tregs via Regulating Monocyte
Chemotactic Protein 1 Secretion
(A–D) BMMSCT (BMMSC) induced a transient reduction in the number of CD3+ T cells and an increase in the number of AnnexinV+7AAD+ double positive
apoptotic CD3+ T cells in peripheral bloodmononuclear cells (PBMNCs; A andB) and bonemarrowmononuclear cells (BMMNCs, n = 5; C andD) at indicated time
points, while FAS/ BMMSC from lprmice (lprBMMSC, n = 5) failed to reduce the number of CD3+ T cells or increase the number of CD3+ apoptotic T cells in
peripheral blood (A and B) and bone marrow (C and D).
(E and F) lprBMMSC transplantation failed to elevate Treg levels (E) and TGFb (F) in C57BL6 mice compared to the BMMSCT group at indicated time points.
(G) lprBMMSC transplantation induced activated T cell apoptosis in a BMMSC/T cell in vitro cocultured system, which was blocked by anti-FASL neutralizing
antibody (1 mg/ml).
(H–K) Activated T cells (green) migrate to BMMSCs (red) in a transwell coculture system (H). lprBMMSCs showed a significantly reduced capacity to induce
activated T cell migration (I), which could be partially rescued by overexpression of monocyte chemotactic protein 1 (mcp-1; J) and totally rescued by over-
expression of fas (K) in lprBMMSCs. The results were representative of three independent experiments. For (K), bar = 100 mm.
(L) Western blot showed that lprBMMSCs express a higher cytoplasm level of MCP-1 than BMMSCs. Overexpression of fas in lprBMMSCs reduced the
expression level of MCP-1 in cytoplasm.
(M) ELISA analysis showed that MCP-1 secretion in culture supernatant was significantly reduced in lprBMMSCs compared to BMMSCs. Overexpression of
mcp-1 and fas in lprBMMSCs significantly elevated MCP-1 secretion in culture supernatant.
(N) ELISA data showed that knockdown of fas expression using siRNA resulted in reduction of MCP-1 level in culture medium compared to control siRNA group.
(O and P) fas siRNA-treated BMMSCs (P) showed reduced T cell migration in transwell coculture system compared to control siRNA group (O). For (P), bar =
100 mm.
*p < 0.05, **p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Figure S6.
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ameliorating disease phenotype in the DSS-induced colitis
model (Figures S5A–S5F).
FAS Is Required for BMMSC-Mediated Therapy
by Recruitment of T Cells
In addition to FASL, BMMSCs also express FAS (Figure S6A). To
examine whether FAS plays a role in BMMSC-based immuno-550 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.therapies, we infused FAS/ BMMSCs, derived from C3MRL-
FASlpr/J mice (lprBMMSCs), into C57BL6 mice and found that
FAS/ lprBMMSCs failed to reduce the number of CD3+
T cells or elevate the number of apoptotic CD3+ T cells in periph-
eral blood and bone marrow (Figures 5A–5D). In addition, we re-
vealed that lprBMMSC transplantation failed to upregulate the
levels of Tregs and TGFb and downregulate Th17 cell level in
peripheral blood (Figures 5E and 5F; S6X). Moreover, fas
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FAS/FAS Ligand and Cell-Based Immunotherapyknockdown BMMSCs using siRNA showed the same effect as
observed in FAS/ lprBMMSC (Figures S6Y–S6EE). When
transplanted into DSS-induced colitis mice, lprBMMSCs neither
provided therapeutic effects on body weight, DAI, and histolog-
ical activity index, nor balanced the levels of Tregs and Th17 cells
(Figures S6B–S6G). In addition, lprBMMSC transplantation failed
to treat Tsk/+ SS mice, showing no rescue of the levels of ANA,
anti-dsDNA IgG and IgM antibodies, creatinine, urine protein,
Grabbed distance, Tregs, or Th17 cells (Figures S6H–S6Q).
Taken together, these data suggest that FAS/ lprBMMSCs,
like FASL/ gldBMMSCs, were unable to ameliorate disease
phenotypes in SS and colitis mouse models.
Next, we investigated the underlying mechanisms by which
lprBMMSC transplantation failed to treat the diseases. We
showed that lprBMMSCs expressed a normal level of FASL by
western blot analysis (Figure S6R) and induced CD3+ T cell
apoptosis in a coculture system (Figure 5G). This was blocked
by anti-FASL neutralizing antibody (Figure 5G), suggesting that
the failure to induce in vivo T cell apoptosis by lprBMMSCs
does not result from the lack of expression of functional FASL.
We therefore hypothesized that FAS expression affects the
BMMSC immunomodulatory property via a non-FASL-related
mechanism, such as regulating the recruitment of T cells. To
test this, we used an in vitro transwell coculture system to
show that activated T cells migrate to BMMSCs to initiate cell-
cell contact (Figure 5H). However, lprBMMSCs showed a signif-
icantly reduced capacity to recruit activated T cells in the cocul-
ture system when compared to control BMMSCs (Figures 5H
and 5I). We then used a cytokine array analysis to determine
that lprBMMSCs express a low level of MCP-1, a member of
the C-C motif chemokine family and a T cell chemoattractant
cytokine (Carr et al., 1994; Figure S6S). Interestingly, overex-
pression ofmcp-1 in lprBMMSCs partially rescued their capacity
to recruit T cells (Figures 5H–5J). Overexpression of fas in
lprBMMSCs resulted in the secretion level of multiple cytokines
being restored (Figures S6S and S6U) and fully rescued their
capacity to recruit T cells (Figures 5H, 5I, and 5K). However,
the expression level of MCP-1 protein in lprBMMSCs was higher
than that in control BMMSCs, and overexpression of fas reduced
MCP-1 cytoplasm protein level in lprBMMSCs (Figure 5L), indi-
cating that FAS regulates MCP-1 secretion, but not expression.
Next, we examined MCP-1 level in the culture supernatant, and
we found that the MCP-1 level in lprBMMSCs was significantly
lower than in BMMSCs (Figure 5M). Overexpression of mcp-1
and fas in lprBMMSCs rescued MCP-1 levels in culture superna-
tant (Figure 5M). We next confirmed that FAS regulated MCP-1
secretion using the siRNA knockdown approach (Figure S6T).
Downregulation of fas expression in BMMSCs resulted in
reduced MCP-1 secretion (Figure 5N), with a corresponding
reduction in the capacity to recruit activated T cells in the cocul-
ture system (Figures 5O and 5P).
In order to confirm that MCP-1 contributes to BMMSC-based
immunoregulation, we isolated BMMSCs from MCP-1 mutant
B6.129S4-Ccl2tm1Rol/J mice and showed that MCP-1/
BMMSCs were defective in reducing the number of CD3+
T cells or elevating apoptotic CD3+ T cells in C57BL6 mice
when compared to control BMMSCs (Figures 6A and 6B). Also,
MCP-1/ BMMSCs failed to upregulate the levels of Tregs
and TGFb within 72 hr posttransplantation (Figures 6C and 6D).The deficiency of inducing T cell apoptosis and Treg upregula-
tion byMCP-1/ BMMSCs was not associated with FASL func-
tion (Figure 6E). WhenMCP-1/BMMSCswere cocultured with
activated T cells in a transwell culture system, the number of
T cells migrating to BMMSCs was significantly reduced
compared to control BMMSCs (Figure 6F). Also, FAS and
MCP-1 play an important role in attracting B cells, NK cells,
and immature dendritic cells (iDCs) in an in vitro culture system
(Figure S7A–S7C). These data indicate that MCP-1 secretion
regulates BMMSC-induced T cell migration (Figure 6G). More-
over, we showed that FAS also regulated the secretion of other
cytokines, such as C-X-C motif chemokine 10 (CXCL-10) and
tissue inhibitor of matrix metalloprotease-1 (TIMP-1) (Figures
S6V and S6W).
Allogenic MSC Transplantation Induced CD3+ T Cell
Apoptosis and Treg Upregulation in Patients with SS
Based on the above results in experimental animal models, we
conducted a pilot clinical investigation to assess whether T cell
apoptosis and Treg upregulation occurred in SS patients treated
with MSC transplantation (MSCT). Five patients (four females
and one male; Table S1), ranging in age from 44 to 61 years
old (average 51.2 ± 7.8 years old) having SS for a duration of
48–480 months (average 163.2 ± 182.1 months) were enrolled
for allogenic MSCT (Sun et al., 2009; Liang et al., 2009), and
peripheral blood was collected at indicated time points (Fig-
ure 7A). Allogenic MSCT significantly reduced the number of
CD3+ T cells and upregulated the number of AnnexinV-positive
apoptotic CD3+ T cells at 6 hr post-MSCT, and decreased
CD3+ T cell number and apoptotic rate to baseline level by
72 hr (Figures 7B and 7C). A reduced number of CD4+ T cells
was also observed at 6 hr post-MSCT (Figure 7D). Importantly,
the frequency of Tregs in peripheral bloodwas significantly upre-
gulated at 72 hr post-MSCT (Figure 7E), aswas that of TGFb (Fig-
ure 7F). Assessment of Modified Rodnan Skin Score (MRSS) and
Health Assessment Questionnaire disease activity index (HAQ-
DI) indicated that MSCT provided optimal treatment for SS
patients at follow-up period (Figures 7G and 7H). Furthermore,
a reduced level of ANA was observed in SS patients at the 12-
month follow-up period (Figure 7J). Interestingly, the MSCs
derived from SS patients (SSMSCs) showed a deficiency in fasl
and fas expression when compared to MSCs derived from
healthy donors (Figures 7K and 7M). SSMSCs showed a reduced
capacity to induce T cell apoptosis (Figure 7L) and secrete MCP-
1 (Figure 7N) by their reduced expression levels of fasl and fas. In
addition, we found that MSCT significantly improved skin ulcers
in a patient (Figure 7I). These early clinical data demonstrate the
safety and efficacy of MSCT in SS patients and improvement of
disease activities at postallogenic MSCT. However, the long-
term effects of MSCT on SS patients will require further
investigation.
DISCUSSION
The FASL/FAS-mediated cell death pathway represents typical
apoptotic signaling in many cell types (Hohlbaum et al., 2000;
Pluchino et al., 2005; Zhang et al., 2008). BMMSCs express
FASL and induce tumor cell apoptosis in vitro (Mazar et al.,
2009). However, it is unknown whether BMMSCs induce T cellCell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc. 551
Figure 6. MCP-1 Plays an Important Role in T Cell Recruitment
(A)MCP-1/ BMMSC transplantation resulted in a slightly reduced number of CD3+ T cells in peripheral blood, but the level of reduction was significantly less
than that of the BMMSCT group.
(B) AnnexinV+7AAD+ double positive apoptotic CD3+T cell percentage was slightly increased in the MCP-1/ BMMSCT group.
(C) Treg level was slightly increased in theMCP-1/ BMMSC-transplanted group at 72 hr posttransplantation, but significantly lower than that of the BMMSCT
group.
(D) TGFb level in serumwas slightly increased in theMCP-1/BMMSC-transplanted group at 72 hr after transplantation compared to 0 hr, but the elevation level
was lower than that of the BMMSCT group.
(E) MCP-1/ BMMSCs showed no significantly reduced capacity in activated T cell apoptosis induction compared to BMMSCs.
(F) When T cells were stimulated with CD3 and CD28 antibody and cocultured with BMMSCs orMCP-1/ BMMSCs in a transwell culture system, the number of
migrated T cells was significantly higher in the BMMSC group than the MCP-1/ BMMSC group.
(G) Schematic diagram showing the mechanism of BMMSC-induced immunotherapies. Bar = 100 mm.
**p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Figure S7.
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Therefore, we transplanted BMMSCs into C57BL6 mice and
demonstrated that BMMSCs, but not FASL-deficient BMMSCs,
induced transient T cell apoptosis. Furthermore, we found
a reduced number of T cells in multiple organs, including periph-
eral blood, bonemarrow, spleen, and lymph node. It appears that
alteration of T cell number, owing to T cell redistribution, is not
supported by the experimental evidence. Since CD3 antibody-
induced T cell apoptosis resulted in immune tolerance (Chate-
noud et al., 1994, 1997), we confirm here that BMMSC-induced
T cell apoptosis upregulates Tregs via high levels of macro-
phage-released TGFb (Kleinclauss et al., 2006; Perruche et al.,
2008). Although transplanted FASL/ gldBMMSCs and fasl
knockdown BMMSCs underwent apoptosis in vivo, they failed
to induce upregulation of Tregs. This evidence further confirms
that T cell, but not transplanted BMMSC, apoptosis is required
for inductive upregulation of Tregs (Perruche et al., 2008).
Despite the expression of functional FASL by FAS/
lprBMMSCs, they failed to induce T cell apoptosis and upregu-
late Tregs in vivo.Mechanistically, FAS controls chemoattractant
cytokine MCP-1 secretion in BMMSCs. Decreased MCP-1
secretion from lprBMMSCs results in the failure to recruit acti-
vated T cells to BMMSCs (Carr et al., 1994; Xu et al., 1996)
and, hence, infusion of FAS/ lprBMMSCs failed to induce552 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.T cell apoptosis in vivo. However, when lprBMMSCs were
directly cocultured with CD3+ T cells, they could induce T cell
apoptosis, suggesting that lprBMMSC may not able to initiate
cell-cell contact with T cells in vivo. Moreover, FAS/
lprBMMSCs show a higher cytoplasm level of MCP-1 than
control BMMSCs, suggesting that FAS regulates MCP-1 secre-
tion, but notMCP-1 production.WhenMCP-1/BMMSCswere
systemically transplanted into C57BL6 mice, CD3+ T cell
apoptosis and Treg upregulation were significantly reduced
compared to that of control BMMSC group, suggesting that
MCP-1 is one of the factors regulating MSC-based immune
tolerance. It was reported that BMMSCs could inhibit CD4/
Th17 T cells with MCP-1 paracrine conversion from agonist to
antagonist (Rafei et al., 2009). Here we showed that MCP-1
helped to recruit T cells to upregulate Tregs. Prospectively, it
will be important to dissect the mechanism by which FAS regu-
lates MCP-1 secretion. In addition to MCP-1 secretion, FAS also
regulates multiple cytokine and chemokine secretions in
BMMSCs, which may extensively affect the recruitment of
T cells. Therefore, MCP-1 may only represent one of those che-
mokines contributing to BMMSC-mediated T cell recruitment.
Significantly, our primary clinical investigation showed that
MSC infusion induced CD3+ T cell apoptosis and Treg upregula-
tion in allogenic MSC-infused SS patients. In our 1–12 month
Figure 7. Allogenic MSC Transplantation Induces CD3+ T Cell Apoptosis and Treg Upregulation in SS Patients
(A) Schema of MSC transplantation in SS patients.
(B) Flow cytometric analysis showed a reduced number of CD3+ T cells from 2 to 72 hr posttransplantation.
(C) AnnexinV-positive apoptotic CD3+ T cells were significantly increased at 6 hr after MSC transplantation.
(D) Flow cytometric analysis showed a reduced number of CD4+ T cells from 2 to 72 hr posttransplantation.
(E) Treg levels in peripheral blood were significantly increased at 72 hr after allogenic MSC transplantation.
(F) Serum level of TGFb was significantly increased in MSC transplantation group at 72 hr posttransplantation.
(G and H) Modified Rodnan Skin Score (MRSS) (G) and Health Assessment Questionnaire disease activity index (HAQ-DI) (H) were significantly reduced after
allogenic MSC transplantation.
(I) Representative images of skin ulcers prior to MSC transplantation (pre-MSC) and at 6 months posttransplantation (post-MSC).
(J) The reduced ANA level was maintained at 12 months after MSC transplantation.
(K) Real-time PCR analysis showed significantly decreased fasl expression in SS patient MSCs (SSMSC) compared to MSCs from a healthy donor (MSC).
(L) SSMSCs exhibited a significantly decreased capacity to induce T cell apoptosis compared to normal MSCs in vitro.
(M) SSMSCs showed a reduced expression of fas by real-time PCR analysis.
(N) MCP-1 secretion level in SSMSCs was significantly lower than that in MSC culture supernatant.
*p < 0.05, **p < 0.01, ***p < 0.005. Error bars: mean ± SD. See also Table S1.
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including cardiovascular and pulmonary insufficiencies, infec-
tion, malignancy, or metabolic disturbances, suggesting the
safety of the MSC therapy in SS patients. The therapeutic effects
of allogenic MSCT were significant as shown by the reduction of
MRSS, the assessment of HAQ-DI, and the improvement in the
quality of life. Furthermore, we demonstrated thatMSCTdramat-
ically improved treatment-refractory skin ulcers.
Thus, we have uncovered a previously unrecognized BMMSC-
mediated therapeuticmechanism bywhich BMMSCs use FAS to
regulate MCP-1 secretion for T cell recruitment and subse-
quently use FASL to induce T cell apoptosis. Macrophages
subsequently take the debris of apoptotic T cells to releasea high level of TGFb, leading to upregulation of Tregs and, ulti-
mately, immune tolerance for immunotherapies. Collaborative
execution of therapeutic effect between FAS and FASL may
therefore represent a new functional role of receptor/ligand in
cell-based therapies.
EXPERIMENTAL PROCEDURES
Animals and Antibodies
Female C57BL6 (BL6), B6CgFblnTSK+/+PldnPa/J, C57BL6-Tg(TcraTcrb)
1100Mjb/J (OT1TCRTG), B6Smn.C3-FASLgld/J (BL6 gld), C3MRL-FASlpr/J
(C3H lpr), and B6.129S4-Ccl2tm1Rol/J mice were purchased from the Jackson
Lab. gld and lpr strains have spontaneous mutations in FASL (FASLgld) and
FAS (FASlpr), respectively, with no other spontaneous mutations. FemaleCell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc. 553
Cell Stem Cell
FAS/FAS Ligand and Cell-Based Immunotherapyimmunocompromised mice (Beige nude/nude XIDIII) were purchased from
Harlan. All animal experiments were performed under the institutionally
approved protocols for the use of animal research (USC #10941 and 11327).
The antibodies used in this study are described in the Supplemental Experi-
mental Procedures.
Isolation of BMMSCs
Mouse BMMSCs were isolated from femurs and tibias and maintained.
Detailed methods are described in the Supplemental Experimental
Procedures.
Isolation of CD11b-Positive Cells
To isolate CD11b-positive phagocytes, mouse splenocytes were isolated and
incubated with PE-conjugated anti-CD11b antibody (BD). After 30 min incuba-
tion on ice, CD11b-positive cells were sorted out using anti-PE magnetic
beads (Miltenyi Biotech) according to the manufacturer’s instructions.
Flow Cytometry Analysis
Whole peripheral blood was stained with anti-CD45, anti-CD3, anti-CD4, and
CD8a antibodies and treated with BD FACS Lysing Solution (BDBioscience) to
get mononuclear cells (MNCs). The apoptotic T cells were detected by staining
with CD3 antibody, followed by Annexin-V Apoptosis Detection Kit I (BD Phar-
Mingen). For fluorescent labeling of cells, BMMSCs or T cells were incubated
with CFSE (SIGMA) for 15 min or PKH-26 (Invitrogen) for 5 min, according to
the manufacturer’s instructions. For Foxp3 intercellular staining, T cells were
stained with anti-CD4, CD8a, and CD25 antibodies (1 mg each) for 30 min on
ice. Next, cells were stained with anti-Foxp3 antibody using Foxp3 staining
buffer kit (eBioscience). For IL17 staining, T cells were stained with anti-CD4
antibody and then stained with anti-IL17 antibody using Foxp3 staining buffer
kit. All samples were analyzed with FACScalibur (BD Bioscience).
Western Blot Analysis
Twenty micrograms of protein was used and SDS-PAGE and western blotting
were performed according to standard procedures. b-actin on the same
membrane served as the loading control. Detailed procedures are described
in Supplemental Experimental Procedures.
Coculture of T Cells with BMMSCs
BMMSCs (0.23106) were seeded on a 24-well culture plate (Corning) and incu-
bated for 24 hr. The prestimulated T cells were directly loaded onto BMMSCs
and cocultured for 2 days. In some experiments, anti-FAS ligand neutralizing
antibody (BD) or caspase 3, 8, or 9 inhibitors (R&D systems) were added to
the coculture. Apoptotic T cells were detected as described above.
T Cell Migration Assay
For T cell migration assay, a transwell system was used. PKH26-stained
BMMSCs (0.23106) were seeded on the lower chamber of a 12-well culture
plate (Corning) with transwell and incubated for 24 hr. The T cells prestimulated
for 48 hr with anti-CD3 and anti-CD28 antibodies were loaded onto the upper
chamber of the transwell and cocultured for 48 hr, then observed under a fluo-
rescent microscope. Green-labeled cell number was counted and normalized
by red-labeled number of MSCs in five representative images.
Overexpression of fasl
293T cells for lentivirus production were seeded in a 10 cm culture dish (Corn-
ing) until 80% confluence was reached. Plasmids with proper proportion (fasl
gene expression vector: psPAX: pCMV-VSV-G [all from Addgene] = 5:3:2),
were mixed in opti-MEM (Invitrogen) with Lipofectamin LTX (Invitrogen) ac-
cording to the protocol of the manufacturer. EGFP expression plasmid (Addg-
ene) was used as a control. The supernatant was collected 24 hr and 48 hr after
transfection and filtered through a 0.45 mm filter to remove cell debris. For
infection, the supernatant containing lentivirus was added into target cell
culture in the presence of 4 mg/ml polybrene (SIGMA), and the transgene
expression was validated by GFP under microscopic observation.
Overexpression of fas andmcp-1
To generate fas and mcp-1 overexpression vectors, a pCMV6-AC-GFP
TrueORF mammalian expression vector system (Origene) was used. fas and554 Cell Stem Cell 10, 544–555, May 4, 2012 ª2012 Elsevier Inc.mcp-1 cDNA clones generated from C57BL6 strain mice were purchased
from Open Biosystems (Huntsville) and amplified by PCR with SgfI and MluI
restriction cutting sites. The PCR products were directly subcloned into
pCR-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Invitro-
gen). After sequencing, fas andmcp-1 cDNAs with SgfI/MluI sites were subcl-
oned into pCMV6-AC-GFP expression vector. All constructs were verified by
sequencing before transfection into cells. After construction, lprBMMSCs
were transfected with cDNAs using LIPOFECTAMINE PLUS reagent (Life
Technologies), according to manufacturer’s instructions, for 48 hr.
Inhibition of FAS and FASL
Expression levels of FAS and FASL on BMMSCs were knocked down using
siRNA transfection according to the manufacturer’s instructions. Fluores-
cein-conjugated control siRNA was used as a control and as amethod of eval-
uating transfection efficacy. All siRNA products were purchased from Santa
Cruz.
Allogenic BMMSCT into Acute Colitis Mice
Acute colitis was induced by administering 3% (w/v) DSS (molecular mass:
36,000–50,000 Da; MP Biochemicals) through drinking water, which was fed
ad libitum for 10 days (Zhang et al., 2010). Passage one BMMSCs,
gldBMMSCs, or lprBMMSCs were infused (13106 cells) into disease model
mice (n = 6) intravenously at day 3 after feeding with DSS water. In the control
group, mice received PBS (n = 6). All mice were harvested at day 10 after being
fed DSS water and were analyzed. Induced colitis was evaluated as previously
described (Alex et al., 2009).
Allogenic BMMSCT into SS Mice
Passage one BMMSCs, gldBMMSCs, or lprBMMSCs were infused (13106
cells) into SSmice intravenously at 8 weeks of age (n = 6). In the control group,
SS mice received PBS (n = 5). All mice were sacrificed at 12 weeks of age for
further analysis. The protein concentration in urine was measured using
Bio-Rad Protein Assay (Bio-Rad).
Allogenic MSCT into SS Patients
MSCs from umbilical cord were sorted out and expanded, following a previous
report (Liang et al., 2009). ExpandedMSCs were intravenously infused into the
SS recipients (13106/kg body weight). The trial was conducted in compliance
with current Good Clinical Practice standards and in accordance with the prin-
ciples set forth under the Declaration of Helsinki, 1989. This protocol was
approved by the IRB of the DrumTower Hospital of Nanjing, UniversityMedical
School, China. Informed consent was obtained from each patient.
Statistical Analysis
Student’s t test was used to analyze statistical difference. p < 0.05 was consid-
ered significant.
SUPPLEMENTAL INFORMATION
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